CN117343004A - 一种2-氨基吡啶类化合物的制备方法 - Google Patents
一种2-氨基吡啶类化合物的制备方法 Download PDFInfo
- Publication number
- CN117343004A CN117343004A CN202311277925.6A CN202311277925A CN117343004A CN 117343004 A CN117343004 A CN 117343004A CN 202311277925 A CN202311277925 A CN 202311277925A CN 117343004 A CN117343004 A CN 117343004A
- Authority
- CN
- China
- Prior art keywords
- aminopyridine
- reaction
- trimethylsilyl
- producing
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ICSNLGPSRYBMBD-UHFFFAOYSA-N alpha-aminopyridine Natural products NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 title claims abstract description 37
- -1 2-aminopyridine compound Chemical class 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 62
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000010791 quenching Methods 0.000 claims abstract description 24
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 15
- 229910052751 metal Inorganic materials 0.000 claims abstract description 10
- 239000002184 metal Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 230000035484 reaction time Effects 0.000 claims abstract description 7
- 150000003930 2-aminopyridines Chemical class 0.000 claims abstract description 6
- 239000000654 additive Substances 0.000 claims abstract description 6
- 230000000996 additive effect Effects 0.000 claims abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 4
- 239000012298 atmosphere Substances 0.000 claims abstract description 3
- 230000001681 protective effect Effects 0.000 claims abstract description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 50
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 23
- 230000000171 quenching effect Effects 0.000 claims description 20
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims description 14
- 239000011698 potassium fluoride Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- 235000019270 ammonium chloride Nutrition 0.000 claims description 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 6
- MTAODLNXWYIKSO-UHFFFAOYSA-N 2-fluoropyridine Chemical compound FC1=CC=CC=N1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 claims description 4
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 claims description 4
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 claims description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 3
- 235000003270 potassium fluoride Nutrition 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- MOVBJUGHBJJKOW-UHFFFAOYSA-N methyl 2-amino-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1N MOVBJUGHBJJKOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000012044 organic layer Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 7
- 125000004185 ester group Chemical group 0.000 claims 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 229910052723 transition metal Inorganic materials 0.000 abstract description 7
- 150000003624 transition metals Chemical class 0.000 abstract description 7
- 239000003054 catalyst Substances 0.000 abstract description 4
- 125000000524 functional group Chemical group 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 27
- 239000012074 organic phase Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000011369 resultant mixture Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- HZNFABRHAXANIU-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CC=CC(C(F)(F)F)=C1 HZNFABRHAXANIU-UHFFFAOYSA-N 0.000 description 4
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
- 150000005749 2-halopyridines Chemical class 0.000 description 2
- GCFOYCVTZWWQDP-UHFFFAOYSA-N 5-(3-nitrophenyl)pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=CC=CC([N+]([O-])=O)=C1 GCFOYCVTZWWQDP-UHFFFAOYSA-N 0.000 description 2
- RSGVKIIEIXOMPY-UHFFFAOYSA-N 5-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC=C(C(F)(F)F)C=N1 RSGVKIIEIXOMPY-UHFFFAOYSA-N 0.000 description 2
- UGSBCCAHDVCHGI-UHFFFAOYSA-N 5-nitropyridin-2-amine Chemical compound NC1=CC=C([N+]([O-])=O)C=N1 UGSBCCAHDVCHGI-UHFFFAOYSA-N 0.000 description 2
- KDVBYUUGYXUXNL-UHFFFAOYSA-N 6-aminopyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C=N1 KDVBYUUGYXUXNL-UHFFFAOYSA-N 0.000 description 2
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 2
- OBYJTLDIQBWBHM-UHFFFAOYSA-N 6-chloropyridin-2-amine Chemical compound NC1=CC=CC(Cl)=N1 OBYJTLDIQBWBHM-UHFFFAOYSA-N 0.000 description 2
- UZALKVXCOUSWSL-UHFFFAOYSA-N 6-fluoropyridin-2-amine Chemical compound NC1=CC=CC(F)=N1 UZALKVXCOUSWSL-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229960003982 apatinib Drugs 0.000 description 2
- 229950003628 buparlisib Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- JACPDLJUQLKABC-UHFFFAOYSA-N methyl 6-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(N)N=C1 JACPDLJUQLKABC-UHFFFAOYSA-N 0.000 description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- HDKKGUCSENOBHD-UHFFFAOYSA-N tert-butyl 6-aminopyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=C(N)N=C1 HDKKGUCSENOBHD-UHFFFAOYSA-N 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- MBTGBRYMJKYYOE-UHFFFAOYSA-N 2,6-difluoropyridine Chemical compound FC1=CC=CC(F)=N1 MBTGBRYMJKYYOE-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- ZIDIKYIZXMYHAW-UHFFFAOYSA-N 2-bromo-6-fluoropyridine Chemical compound FC1=CC=CC(Br)=N1 ZIDIKYIZXMYHAW-UHFFFAOYSA-N 0.000 description 1
- LXOHKRGLGLETIJ-UHFFFAOYSA-N 2-chloro-6-fluoropyridine Chemical compound FC1=CC=CC(Cl)=N1 LXOHKRGLGLETIJ-UHFFFAOYSA-N 0.000 description 1
- UUODQIKUTGWMPT-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC=C(C(F)(F)F)C=N1 UUODQIKUTGWMPT-UHFFFAOYSA-N 0.000 description 1
- XOZAJNLUAODXSP-UHFFFAOYSA-N 2-fluoro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)N=C1 XOZAJNLUAODXSP-UHFFFAOYSA-N 0.000 description 1
- JYVSYFGHYFXYBE-UHFFFAOYSA-N 3-[5-(cyclopropylmethyl)-1,3,4-oxadiazol-2-yl]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine Chemical compound NC1=NC=C(C=C1C1=NN=C(CC2CC2)O1)C1=CN(N=C1)C1CCNCC1 JYVSYFGHYFXYBE-UHFFFAOYSA-N 0.000 description 1
- VRLVOMUVHHHJHB-UHFFFAOYSA-N 6-fluoropyridine-3-carbonitrile Chemical compound FC1=CC=C(C#N)C=N1 VRLVOMUVHHHJHB-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- VPJXPDLMACOGIZ-UHFFFAOYSA-N 8-[2-amino-3-chloro-5-(1-methylindazol-5-yl)pyridin-4-yl]-2,8-diazaspiro[4.5]decan-1-one Chemical compound C=1C=C2N(C)N=CC2=CC=1C1=CN=C(N)C(Cl)=C1N(CC1)CCC21CCNC2=O VPJXPDLMACOGIZ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 229940125407 FGF401 Drugs 0.000 description 1
- 229940125408 FGFR4 inhibitor Drugs 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HLYBWNNPVXFCPZ-UHFFFAOYSA-N methyl 6-fluoropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(F)N=C1 HLYBWNNPVXFCPZ-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229950003687 ribociclib Drugs 0.000 description 1
- 229940121323 roblitinib Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- RZWMKWGTXCIWLV-UHFFFAOYSA-N tert-butyl 6-fluoropyridine-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=C(F)N=C1 RZWMKWGTXCIWLV-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明公开了一种2‑氨基吡啶类化合物的制备方法,其特征在于,包括以下步骤:在保护性气氛下,将式Ⅱ所示的2‑氟吡啶类化合物与氨源双(三甲基硅烷基)氨基金属盐在一定温度、添加剂作用下进行反应,然后加入淬灭剂淬灭反应,再经后处理制得式Ⅰ所示的2‑氨基吡啶类化合物。本发明制备方法具有反应条件温和、反应时间短、适用底物范围广、官能团兼容性好、区域选择性良好的特点,同时无需昂贵的过渡金属催化剂,也无需高温高压反应设备,所用试剂廉价易得,操作简便易行,这为实现实验室大规模制备2‑氨基吡啶类化合物提供了一种新的可行性方法。
Description
技术领域
本发明属于化学合成技术领域,特别涉及一种2-氨基吡啶类化合物的制备方法。
背景技术
2-氨基吡啶是一类重要的含氮芳香杂环化合物,该类芳香杂环结构单元不仅是阿帕替尼(Apatinib)、奈伟拉平(Nevirapine)、维罗非尼(Vemurafenib)、瑞博西尼(Ribociclib)、哌柏西利(Palbociclib)多个药物的主要骨架,也是现代药物研发中的重要结构单元,存在于许多药物活性分子的结构中,还常被用作活性分子和配体的合成前体。
例如,XZB-0004(SLC-391,结构式见图1),为一种有效的、高选择性的、可口服的小分子AXL靶向抑制剂,临床前研究数据表明,XZB-0004化合物在不同动物模型包括NSCLC、结肠癌、慢性髓系白血病(CML)和急性髓系白血病(AML)模型中均有良好的疗效。Roblitinib(FGF-401,结构式见图1),为一种有效的、选择性的FGFR4抑制剂,其对p110α/β/δ/γ的IC50值分别是52nM/166nM/116nM/262nM;Buparlisib(其结构式见图1)可通过PI3K-AKT-mTOR信号通路抑制肿瘤生长,诱导细胞凋亡,Buparlisib还可以抑制神经胶质瘤的生长,具有抗癌活性;而基于BKM120优化得到的compound26(其结构式见图1)在HT-29结直肠癌异种移植物模型中表现出更高的效率;CCT-251921(其结构式见图1),为一种高效的、选择性的和口服生物利用度高的CDK8抑制剂,IC50为2.3nm。
目前,已报道的合成2-氨基吡啶的方法很多,常用的方法是通过以2-卤代吡啶为原料制备,大致归纳为两类:一是以通过SNAr反应(芳香族亲核取代反应)合成2-氨基吡啶,二是通过过渡金属催化的偶联反应合成2-氨基吡啶。但上述两类方法均存在明显缺陷,具体如下:(1)通过SNAr反应合成2-氨基吡啶,比较常见的是通过2-F、2-Cl或2-Br吡啶与氨水进行反应来合成。但此类方法往往需要高温、高压反应条件,不仅需要特殊的高压反应设备,且反应时间也往往较长。此外,由于反应条件比较剧烈,对底物官能团的兼容性也比较有限,进一步限制了此方法的应用。例如,WO2017/211303公开了使用氨水和含2-氟吡啶结构在二甲亚砜溶液100度反应40小时。文献1(Journal of Organic Chemistry,1988,vol.53,#12,p.2740-2744)中也使用氨水和含2-氟吡啶结构在130度反应,反应时间长达72h。中国专利CN108003093公开了使用氨水和含2-氟吡啶结构在130度,22502.3Torr的高压下进行反应。同样,对于含2-氯吡啶结构作为原料的情况也存在同样的问题,中国专利CN110143916公开了使用氨水和含2-氯吡啶结构在10℃,4500.45-12001.2Torr的压力下反应28h。对于含2-溴吡啶结构作为原料的情况也存在同样的问题,例如美国专利US2004/199024公开了使用氨水和含2-溴吡啶结构在1900℃,18751.9Torr的压力下进行反应。(2)通过过渡金属催化的偶联反应合成2-氨基吡啶,这类方法是通过2-Cl,2-Br,2-I吡啶与相应的氨基前体在过渡金属的催化进行偶联反应,然后再脱去相应的保护基得到2-氨基吡啶,相比于SNAr反应,这类方法的反应条件相对温和,但其往往需要昂贵的过渡金属催化剂。另外,由于重金属在API中残留限度的规定,在药物研发中,这类方法往往涉及残留金属的去除,进一步增加了药物合成的成本。
此外,也有文献报道了以LHMDS作为氨源与2-卤代吡啶进行偶联合成2-氨基吡啶,但这类方法同样需要昂贵的过渡金属催化剂,例如WO2018/65365公开使用了Pd2(dba)3和CyJohnPhos进行偶联,极大增加了成本,同时也增加了重金属残留的可能性。
发明内容
针对上述现有技术存在的问题,本发明的目的在于提供了一种2-氨基吡啶类化合物的制备方法。该制备方法不仅具有反应条件温和、操作简便、反应时间短、适用底物范围广、官能团兼容性好的特点。
为了实现上述目的,本发明采用了如下技术方案:
一种2-氨基吡啶类化合物的制备方法,包括以下步骤:在保护性气氛下,将下式Ⅱ所示的2-氟吡啶类化合物与氨源双(三甲基硅烷基)氨基金属盐在一定温度、添加剂作用下进行反应,然后加入淬灭剂淬灭反应,再经后处理制得下式Ⅰ所示的2-氨基吡啶类化合物:
其中,R选自卤素、C1-C10烷基、取代C1-C10烷基、硝基、酯基、芳环、杂芳环中的一种,所述取代C1-C10烷基为C1-C10烷基上的1个或1个以上的H被取代基A取代的C1-C10烷基,所述取代基A选自卤素、-CF3、C1-C3烷基、C1-C3烷氧基或苯基。
优选地,所述氨源双(三甲基硅烷基)氨基金属盐与2-氟吡啶类化合物的摩尔比为1~5:1,例如,所述氨源双(三甲基硅烷基)氨基金属盐与2-氟吡啶类化合物的摩尔比可选自:1:1、2:1、3:1、4:1、5:1;进一步优选为2:1。
优选地,所述反应温度为-60℃~80℃,例如,反应温度选自:-60℃、-40℃、-20℃、0℃、20℃、室温、40℃、60℃、70℃或80℃;进一步优选为室温。
优选地,所述反应时间为1~4h;例如,反应时间选自1h、2h、3h、4h;进一步优选为2h;
优选地,所述有机溶剂为四氢呋喃、乙醚、甲基四氢呋喃、甲基叔丁基醚中的一种或者两种以上的组合,进一步优选为四氢呋喃。
优选地,所述氨源双(三甲基硅烷基)氨基金属盐为LHMDS(lithium hexamethyl-disilazine,双三甲基硅基胺基锂)、NaHMDS(双(三甲基硅基)氨基钠)、KHMDS(双(三甲基硅基)氨基钾)中的一种,进一步优选为KHMDS。
优选地,所述添加剂为四甲基氟化铵、四丁基氟化铵、氟化铯和氟化钾中的一种,进一步优选为氟化钾。
优选地,所述淬灭剂为饱和氯化铵水溶液、柠檬酸、稀盐酸中的一种,进一步优选为饱和氯化铵水溶液。
优选地,所述后处理具体包括:在反应淬灭后,向所获混合物中加入萃取剂进行萃取,取有机层,洗涤,用干燥剂进行干燥,再采用柱层析进行纯化分离,获得2-氨基吡啶类化合物。
与现有技术相比,本发明具备如下有益效果:
本发明通过以氨源双(三甲基硅烷基)氨基金属盐与2-氟吡啶类化合物为原料,在一定温度、添加剂作用下进行反应,成功地制备了2-氨基吡啶类化合物。本发明制备方法具有反应条件温和、反应时间短、适用底物范围广、官能团兼容性好、区域选择性良好的特点,同时无需昂贵的过渡金属催化剂,也无需高温高压反应设备,所用试剂廉价易得,操作简便易行,这为实现实验室大规模制备2-氨基吡啶类化合物提供了一种新的可行性方法。
附图说明
为了更清楚地说明本发明实施例中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为2-氨基吡啶类化合物的结构式。
具体实施方式
以下描述中,为了说明而不是为了限定,提出了诸如特定系统结构、技术之类的具体细节,以便透彻理解本发明实施例。然而,本领域的技术人员应当清楚,在没有这些具体细节的其它实施例中也可以实现本发明。
实施例1
制备6-溴吡啶-2-胺,其化学结构式如下:
具体步骤:在氮气保护下,将2-溴-6-氟吡啶(200mg,1.1mmol)溶于无水THF(2mL),加入KF(6.4mg,0.11mmol),然后于室温下滴加1M KHMDS的THF溶液(2.2mL,2.2mmol),滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3),合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,进一步经硅胶柱层析纯化,得到140mg的6-溴吡啶-2-胺,收率71.2%。LC-MS(ESI+,液相色谱质谱联用):m/z173.1,175.1;1HNMR(300MHz,DMSO-d6)δ7.30-7.26(m,1H),6.70-6.60(m,1H),6.45-6.35(m,1H),6.37(s,2H)。
实施例2
制备6-氟吡啶-2-胺,其化学结构式如下:
具体步骤:在氮气保护下,将2,6-二氟吡啶(500mg,4.3mmol)溶于无水THF(5mL),加入KF(24.9mg,0.43mmol),然后于室温下滴加1M KHMDS的THF溶液(8.6mL,8.6mmol)。滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(5mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(5mL×3),合并有机相,饱和食盐水洗涤(5mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化得到370mg 6-氟吡啶-2-胺,收率76%。LC-MS(ESI+):m/z113.2;1H-NMR(CDCl3):δ7.53(m,1H),6.36(dd,J=2.1,7.8Hz,1H),6.26(dd,J=2.1,7.8Hz,1H),4.56(brs,2H)。
实施例3
制备6-氯吡啶-2-胺,其化学结构式如下:
具体步骤:在氮气保护下,将6-氟-2-氯吡啶(100mg,0.7mmol)溶于无水THF(1mL),加入KF(4.1mg,0.07mmol),然后于室温下滴加1M KHMDS的THF溶液(1.4mL,1.4mmol),滴毕,于室温反应2h,经TLC检测,反应完全向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3),合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层纯化得到81mg 6-氯吡啶-2-胺,收率83%。LC-MS(ESI+):m/z 129.2,131.2;1H NMR(300MHz,CDCl3)δ7.31(t,J=7.75Hz,1H),6.58(d,J=7.58Hz,1H),6.35(d,J=7.91Hz,1H),5.12(brs,2H)。
实施例4
制备5-硝基吡啶-2-胺,其化学结构式如下:
具体步骤:在氮气保护下,将2-氟-5-硝基吡啶(100mg,0.7mmol)溶于无水THF(1mL),加入KF(4.1mg,0.07mmol),然后于室温下滴加1M KHMDS的THF溶液(1.4mL,1.4mmol),滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3),合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层纯化得到87.1mg 5-硝基吡啶-2-胺,收率89%。LC-MS(ESI+):m/z 140.1;1H NMR(DMSO-d6,300MHz):δ8.85(d,J=2.4Hz,1H),8.12(d,J=9.0Hz,1H),7.53(brs,2H),6.50(d,J=9.0Hz,1H)。
实施例5
制备6-氨基烟酸甲酯,其化学结构式如下:
具体步骤:在氮气保护下,将6-氟烟酸甲酯(100mg,0.6mmol)溶于无水THF(0.5mL),加入KF(3.7mg,0.06mmol),然后于室温下滴加1M KHMDS的THF溶液(1.3mL,1.3mmol)。滴毕,于室温反应2h。经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3),合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得35.3mg 6-氨基烟酸甲酯,收率36%。LC-MS(ESI+):m/z153.1;1HNMR(300MHz,DMSO-d6)δ8.50(s,1H),7.83(d,J=8.8Hz,1H),6.82(brs,2H),6.46(d,J=8.8Hz,1H),3.75(s,3H)。
实施例6
制备6-氨基烟酸叔丁酯,其化学结构式如下:
具体步骤为:在氮气保护下,将6-氟烟酸叔丁酯(50mg,0.2mmol)溶于无水THF(0.5mL),加入KF(1.5mg,0.02mmol),然后于室温下滴加1M KHMDS的THF溶液(0.4mL,0.4mmol)。滴毕,于室温反应1h。经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(1mL×3),合并有机相,饱和食盐水洗涤(1mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得35mg 6-氨基吡啶-3-羟酸叔丁酯,收率71%。LC-MS(ESI+):m/z 195.1;1HNMR(300MHz,DMSO-d6)δ8.45(s,1H),7.64(d,J=8.5Hz,1H),6.74(brs,2H),6.45(s,J=8.7Hz,1H),1.50(s,9H)。
实施例7
制备5-(三氟甲基)吡啶-2-胺,其化学结构式如下:
具体步骤为:在氮气保护下,将2-氟-5-三氟甲基吡啶(100mg,0.6mmol)溶于无水THF(0.5mL),加入KF(3.5mg,0.067mmol),然后于室温下滴加1M KHMDS的THF溶液(1.2mL,1.2mmol),滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3)。合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得65.8mg 2-氨基-5-三氟甲基吡啶,收率67%。LC-MS(ESI+):m/z 163.1;1HNMR(300MHz,DMSO-d6)δ8.21(s,1H),7.64(d,J=10.6Hz,1H),6.71(brs,2H),6.53(d,J=8.7Hz,1H)。
实施例8
制备2-氨基-5-氰基吡啶,其化学结构式如下:
具体步骤为:在氮气保护下,将5-氰基-2-氟吡啶(100mg,0.8mmol)溶于无水THF(0.5mL),加入KF(4.8mg,0.08mmol),然后于室温下滴加1M KHMDS的THF溶液(1.6mL,1.6mmol),滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3),合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得83mg 2-氨基-5-氰基吡啶,收率85%。LC-MS(ESI+):m/z 120.0;1HNMR(300MHz,DMSO-d6)δ8.30(s,1H),7.69(d,J=8.8Hz,1H),7.01(brs,2H),6.49(d,J=8.7Hz,1H)。
实施例9
制备5-(3-硝基苯基)吡啶-2-胺,其化学结构式如下:
具体步骤:在氮气保护下,将2-氟-5-(3-硝基苯基)吡啶(100mg,0.5mmol)溶于无水THF(0.5mL),加入KF(2.7mg,0.05mmol),然后于室温下滴加1M KHMDS的THF溶液(0.9mL,0.9mmol),滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3)。合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得52.2mg 5-(3-硝基苯基)吡啶-2-胺,收率53%。LC-MS(ESI+):m/z 216.2;1HNMR(300MHz,DMSO-d6)δ8.40-8.37(m,2H),8.14-8.10(m,2H),7.88-7.84(m,1H),7.17(t,J=8.0Hz,1H),6.60(d,J=8.6Hz,1H),6.30(brs,2H)。
实施例10
制备5-(3-(三氟甲基)苯基)吡啶-2-胺,其化学结构式如下:
具体步骤:在氮气保护下,将2-氟-5-(3-(三氟甲基)苯基)吡啶(100mg,0.4mmol)溶于无水THF(0.5mL),加入KF(2.4mg,0.04mmol),然后于室温下滴加1M KHMDS的THF溶液(0.8mL,0.8mmol)。滴毕,于室温反应2h。经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3),合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得63.2mg 5-(3-(三氟甲基)苯基)吡啶-2-胺,收率64%。LC-MS(ESI+):m/z 239.3;1HNMR(300MHz,DMSO-d6)δ7.83-7.78(m,2H),7.69(t,J=7.3Hz,1H),7.56(t,J=7.5Hz,1H),7.40-7.32(m,2H),6.51(d,J=8.5Hz,1H),6.10(brs,2H)。
实施例11
制备5-(3-(三氟甲基)苯基)吡啶-2-胺,其化学结构式如下:
具体步骤:氮气保护下,将2-氟-5-(3-(三氟甲基)苯基)吡啶(100mg,0.4mmol)溶于无水THF(0.5mL),加入KF(3.3mg,0.06mmol),然后于室温下滴加1M KHMDS的THF溶液(0.8mL,0.8mmol),滴毕,于室温反应2h,经TLC检测,反应完全,向反应溶液中滴加饱和氯化铵水溶液(2mL)进行淬灭反应,淬灭反应后将所得混合物用乙酸乙酯萃取(2mL×3)。合并有机相,饱和食盐水洗涤(2mL×3),分出有机相,经无水硫酸钠干燥,过滤,减压浓缩,得粗品,经硅胶柱层析纯化,得65.8mg 5-(3-(三氟甲基)苯基)吡啶-2-胺,收率67%。LC-MS(ESI+):m/z 239.3;1HNMR(300MHz,DMSO-d6)δ7.83-7.78(m,2H),7.69(t,J=7.3Hz,1H),7.56(t,J=7.5Hz,1H),7.40-7.32(m,2H),6.51(d,J=8.5Hz,1H),6.10(brs,2H)。
本发明不局限于上述具体的实施方式,本领域的普通技术人员从上述构思出发,不经过创造性的劳动,所做出的种种变换,均落在本发明的保护范围之内。
Claims (8)
1.一种2-氨基吡啶类化合物的制备方法,其特征在于,包括以下步骤:在保护性气氛下,将下式Ⅱ所示的2-氟吡啶类化合物与氨源双(三甲基硅烷基)氨基金属盐在一定温度、添加剂作用下进行反应,然后加入淬灭剂淬灭反应,再经后处理制得下式Ⅰ所示的2-氨基吡啶类化合物:
其中,R选自卤素、C1-C10烷基、取代C1-C10烷基、硝基、酯基、芳环、杂芳环中的一种。
2.根据权利要求1所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述氨源双(三甲基硅烷基)氨基金属盐与2-氟吡啶类化合物的摩尔比为1~5:1。
3.根据权利要求2所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述反应温度为-60~80℃,所述反应时间为1~4h。
4.根据权利要求2所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述有机溶剂为四氢呋喃、乙醚、甲基四氢呋喃、甲基叔丁基醚中的一种或者两种以上的组合。
5.根据权利要求2所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述氨源双(三甲基硅烷基)氨基金属盐为双三甲基硅基胺基锂、双(三甲基硅基)氨基钠、双(三甲基硅基)氨基钾中的一种。
6.根据权利要求2所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述添加剂为四甲基氟化铵、四丁基氟化铵、氟化铯和氟化钾中的一种。
7.根据权利要求1所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述淬灭剂为饱和氯化铵水溶液、柠檬酸、稀盐酸中的一种。
8.根据权利要求1所述的2-氨基吡啶类化合物的制备方法,其特征在于,所述后处理具体包括:在反应淬灭后,向所获混合物中加入萃取剂进行萃取,取有机层,洗涤,用干燥剂进行干燥,再采用柱层析进行纯化分离,获得2-氨基吡啶类化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311277925.6A CN117343004A (zh) | 2023-09-28 | 2023-09-28 | 一种2-氨基吡啶类化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311277925.6A CN117343004A (zh) | 2023-09-28 | 2023-09-28 | 一种2-氨基吡啶类化合物的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117343004A true CN117343004A (zh) | 2024-01-05 |
Family
ID=89370341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311277925.6A Pending CN117343004A (zh) | 2023-09-28 | 2023-09-28 | 一种2-氨基吡啶类化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117343004A (zh) |
-
2023
- 2023-09-28 CN CN202311277925.6A patent/CN117343004A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5636054B2 (ja) | Hivインテグラーゼ阻害活性を有する化合物の製造方法 | |
AU2004236085B2 (en) | Processes for producing 3-substituted 2-chloro-5-fluoropyridine or salt thereof | |
JP5817079B2 (ja) | 6−(7−((1−アミノシクロプロピル)メトキシ)−6−メトキシキノリン−4−イルオキシ)−n−メチル−1−ナフトアミド、またはそれの薬学的に許容される塩を調製するための方法 | |
CN101605760A (zh) | 将某些取代的硫亚胺氧化为杀虫性磺基肟的方法 | |
CN110183378B (zh) | 一种烟酰胺的衍生物及其催化合成方法 | |
CN107973779B (zh) | 一种n-(2-吡啶/嘧啶基)吲哚衍生物的制备方法 | |
CN114276354B (zh) | 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用 | |
WO2006035459A1 (en) | An improved process for the production of derivatives of thiozolidinediones and their precursors | |
EP2123639B1 (en) | Process for production of 2,3'-bipyridyl-6'-one | |
CN108148044B (zh) | 酰胺类化合物及该化合物制备富马酸沃诺拉赞的方法 | |
CN117343004A (zh) | 一种2-氨基吡啶类化合物的制备方法 | |
CN112645871B (zh) | N-cf2h-1,2-二氢吡啶-2-酮化合物的合成方法 | |
KR20160027536A (ko) | 실로도신 합성에 유용한 중간체의 제조방법 | |
JPWO2009028608A1 (ja) | オルト位がヨウ素置換されたフェノール誘導体の製造方法 | |
CN109912640B (zh) | 一种2-吡咯烷酮类化合物的制备方法 | |
CN110483391B (zh) | 一种烟酰亚胺酰胺衍生物的五组分合成方法 | |
CN109748809B (zh) | 一种合成2-取代氨基-1,4-萘醌衍生物的方法 | |
CN110423215B (zh) | 一种查尔酮吡啶盐及其制备方法和应用 | |
KR100510389B1 (ko) | [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-클로로-2-티에닐)메틸]프로필]아미노]-3H-이미다조[4,5-b]피리딘-3-일]-N-에틸-2,3-디하이드록시사이클로펜탄카복스아미드의 제조방법 | |
JP3805788B2 (ja) | シアノピリジン類の製造方法 | |
CN114160206B (zh) | 一种催化合成光学活性吲哚类化合物的催化剂、应用、合成方法及光学活性吲哚类化合物 | |
AU2017258665A1 (en) | Process for the preparation of herbicidal compounds | |
JP2001081074A (ja) | アリールピリジン誘導体の製造法 | |
KR20240038024A (ko) | B형 간염 바이러스 뉴클레오캡시드 억제제의 제조 방법 | |
JP4004082B2 (ja) | 環状ニトログアニジン誘導体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |